Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Non-diabetic Glomerulonephritis
NCT05283057Phase 3Completed
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in Glomerulonephritis (GN), proteinuria, sponsored by Kasr Al Ainy Hospital. Started Feb 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
Glomerulonephritis (GN)proteinuria
Beyond the preview
Go deeper on NCT05283057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283057.